High lymphoid enhancer-binding factor expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia

Hematology Reviews

Volumn 2, Issue 1, 2010, Pages 24-27

  Erdfelder, Felix ^a   Hertweck, Magdalena ^a   Filipovich, Alexandra ^a   Uhrmacher, Sabrina ^a   Kreuzer, Karl Anton ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

CD38; Chronic lymphocytic leukemia (CLL); Fibromodulin; Lymphoid enhancer binding factor 1(LEF1); Zeta associated protein (ZAP70)

Indexed keywords

CD38 ANTIGEN; FIBROMODULIN; LYMPHOID ENHANCER FACTOR 1; MESSENGER RNA; PROTEIN KINASE ZAP 70;

ARTICLE; BINET A STAGE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PATIENT MONITORING; PERIPHERAL LYMPHOCYTE; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT;

EID: 77953370036     PISSN: 19706804     EISSN: 19706790     Source Type: Journal    
DOI: 10.4081/hr.2010.e3     Document Type: Article

References (20)

1. Behrens J, von Kries JP, Kuhl M, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature 1996;382:638-42.
2. Huber O, Korn R, McLaughlin J, et al. Nuclear localization of beta-catenin by interaction with transcription factor LEF- 1. Mech Dev 1996;59:3-10.
3. Reya T, O'Riordan M, Okamura R, et al. Wnt signaling regulates B lymphocyte pro- liferation through a LEF-1 dependent mechanism. Immunity 2000;13:15-24.
4. Wang W, Ji P, Steffen B, et al. Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias. Acta Biochim Biophys Sin (Shanghai) 2005;37:173-80.
5. Li Y, Wang L, Zhang M, et al. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expres- sion, prostate cancer growth, and invasion. Cancer Res 2009;69:3332-8.
6. Nguyen A, Rosner A, Milovanovic T, et al. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression. Int J Oncol 2005;27:949-56.
7. Jelinek DF, Tschumper RC, Stolovitzky GA, et al. Identification of a global gene expression signature of B-chronic lympho- cytic leukemia. Mol Cancer Res 2003;1: 346-61.
8. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lym- phocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625-38.
9. Roman-Gomez J, Cordeu L, Agirre X, et al. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood 2007;109:3462-9.
10. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy- chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351: 893-901.
11. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independ- ent prognostic variables in chronic lym-phocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-9.
12. Vallat L, Magdelenat H, Merle-Beral H, et al. The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood 2003;101:4598-606.
13. Zenz T, Benner A, Dohner H, et al. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle 2008;7:3810-4.
14. Malcikova J, Smardova J, Rocnova L, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 2009; 114:5307.
15. Roche Applied Science Technical Note No. [Hematology Reviews 2010; 2:e3] LC 13/2001 (31), 4. Calibrator Normalized Relative Quantification, http://www.gene_quantification.de/roche-rel-quant.pdf.
16. Rasmussen R. Quantification on the Light Cycler. In: rapid cycle real-time PCR, meth- ods and applications. Meuer S, Wittwer C, Nakagawara K, Eds. Heidelberg: Springer Press, 2000, pp 21-34.
17. Sasaki T, Suzuki H, Yagi K, et al. Lymphoid enhancer factor 1 makes cells resistant to transforming growth factor beta-induced repression of c-myc. Cancer Res 2003;63: 801-6.
18. Rivat C, Le FN, Sabbah M, et al. Synergistic cooperation between the AP-1 and LEF-1 transcription factors in activation of the matrilysin promoter by the src oncogene: implications in cellular invasion. FASEB J 2003;17:1721-3.
19. Aoki M, Hecht A, Kruse U, et al. Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proc Natl Acad Sci USA 1999;96:139-44.
20. Petropoulos K, Arseni N, Schessl C, et al. Anovel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med 2008;205:515-22.